11.05

3.58% -0.41

Mink Therapeutics Inc (INKT)

Overview News Price History Financials Discussions Forecast

Mink Therapeutics Inc stock is traded at $11.05, with a volume of 18,380. It is down -3.58% in the last 24 hours and down -9.35% over the past month. MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Previous Close:

$11.46

Open:

$11.53

24h Volume:

18,380

Relative Volume:

0.49

Market Cap:

$55.05M

Revenue:

Net Income/Loss:

$-12.49M

P/E Ratio:

-3.7271

EPS:

-2.9648

Net Cash Flow:

$-5.93M

1W Performance:

-5.31%

1M Performance:

-9.35%

6M Performance:

-10.89%

1Y Performance:

+42.95%

1-Day Range:

$11.04

$11.56

1-Week Range:

$10.48

$11.97

52-Week Range:

$8.4801

$76.00

Mink Therapeutics Inc Stock (INKT) Company Profile

Name

Mink Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

212-994-8250

Address

149 FIFTH AVENUE, NEW YORK

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

INKT's Discussions on Twitter

Compare INKT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INKT Mink Therapeutics Inc	11.05	55.05M	0	-12.49M	-5.93M	-2.9648
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-15-25	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-14-25	Downgrade	William Blair	Outperform → Mkt Perform

Mink Therapeutics Inc Stock (INKT) Latest News

Jul 10, 2026

Mink Therapeutics (INKT) Proxy filing Summary - Quartr

Jul 10, 2026

Mink Therapeutics (INKT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr

Jul 10, 2026

Jul 08, 2026

MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 29, 2026

MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell 3000E Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 26, 2026

MiNK Therapeutics Advances Phase 2 Trial of agenT-797 in Severe Pneumonia: What Investors Should Watch - TipRanks

Jun 26, 2026

Enterprise value to EBITDA forward of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView

Jun 26, 2026

MiNK Therapeutics, Inc. Actuals & Estimates (NASDAQ:INKT) - TradingView

Jun 26, 2026

Price to earnings forward of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView

Jun 26, 2026

Jun 25, 2026

Price to sales forward of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView

Jun 25, 2026

INKT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

MiNK Therapeutics Stockholders Back Directors, Ratify Auditor - The Globe and Mail

Jun 24, 2026

Jun 23, 2026

Total liabilities & shareholders' equities of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView

Jun 23, 2026

Form 8K Mink Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa

Jun 23, 2026

MiNK Therapeutics (INKT) investors reelect board members and ratify KPMG at 2026 meeting - Stock Titan

Jun 23, 2026

Jun 22, 2026

MiNK Therapeutics (INKT) Edges Higher, Approaching Key Resistance at $12.88Liquidity Sweep - dars.gov.et

Jun 22, 2026

Jun 21, 2026

Avoiding Lag: Real-Time Signals in (INKT) Movement - Stock Traders Daily

Jun 21, 2026

Inventory turnover of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView

Jun 21, 2026

Diluted net income available to common stockholders of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView

Jun 21, 2026

Jun 20, 2026

After tax other income/expense of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView

Jun 20, 2026

Jun 19, 2026

Book value per share of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView

Jun 19, 2026

Jun 18, 2026

MiNK Therapeutics, Inc. Cash Flow – DUS:6Q40 - TradingView

Jun 18, 2026

Debt to equity ratio of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView

Jun 18, 2026